{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:34Z","timestamp":1791925654968,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah","award":["D1435-749-141"],"award-info":[{"award-number":["D1435-749-141"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jmgm.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T08:22:51Z","timestamp":1445761371000},"page":"226-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A structural insight into the inhibitory mechanism of an orally active PI3K\/mTOR dual inhibitor, PKI-179 using computational approaches"],"prefix":"10.1016","volume":"62","author":[{"family":"Mohd Rehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2015.10.005_bib0005","unstructured":"W.B. Stewart, C.P. Wild, World Cancer Report, International agency for research on cancer (IARC), world health organization (WHO). www.iarc.fr\/en\/publications\/books\/wcr\/wcr-order.php. (2014)."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/mTOR Dual Inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0030","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2174\/092986711796011229","article-title":"Progress in the preclinical discovery and clinical development of class I and dual class I\/IV phosphoinositide 3-kinase (PI3K) inhibitors","volume":"18","author":"Shuttleworth","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0040","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","article-title":"The PIK3CA gene is mutated with high frequency in human breast cancers","volume":"3","author":"Bachman","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0055","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.onc.1208304","article-title":"PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas","volume":"24","author":"Lee","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0060","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0065","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0070","first-page":"7426","article-title":"The phosphatidylinositol 3\u2032-kinase p85\u03b1 gene is an oncogene in human ovarian and colon tumors","volume":"61","author":"Philp","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/46319","article-title":"Structural insights into phosphoinositide 3-kinase catalysis and signalling","volume":"402","author":"Walker","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"Helena","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0100","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/jm2009327","article-title":"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-Kinase (PI3K)\/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer","volume":"54","author":"Sutherlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"mTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ceb.2008.12.011","article-title":"PI3K and mTOR inhibitors\u00eda new generation of targeted anticancer agents","volume":"21","author":"Brachmann","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2011.02.008","article-title":"Targeting the mTOR kinase domain: the second generation of mTOR inhibitors","volume":"16","author":"Zhang","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00894-011-1184-3","article-title":"Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors","volume":"18","author":"Tanneeru","year":"2011","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0140","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1158\/0008-5472.CAN-07-2154","article-title":"A dual phosphoinositide-3-kinase a\/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma","volume":"67","author":"Fan","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0145","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0150","first-page":"615","article-title":"PI3K pathway-directed therapeutic strategies in cancer","volume":"11","author":"Agarwal","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0155","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K\/mTOR Kinase Inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0160","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5- triazine) derivatives: potent adenosine 5\u2032-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0165","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.bmcl.2010.07.104","article-title":"PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) inhibitor","volume":"20","author":"Venkatesan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1023\/A:1011115820450","article-title":"DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases","volume":"15","author":"Ewing","year":"2001","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera-a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0180","series-title":"The PyMOL Molecular Graphics System","author":"DeLano","year":"2002"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0185","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Eng."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0195","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/bip.21220","article-title":"A spectroscopic investigation into the interactions of 3\u2032-O-carboxy esters of thymidine with bovine serum albumin","volume":"91","author":"Ghosh","year":"2009","journal-title":"Biopolymers"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0200","series-title":"\u2018Naccess\u2019, Computer Program Technical Report","author":"Hubbard","year":"1993"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1016357811882","article-title":"Further development and validation of empirical scoring functions for structure-based binding affinity prediction","volume":"16","author":"Wang","year":"2002","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0210","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/jm0203783","article-title":"Comparative evaluation of 11 scoring functions for molecular docking","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0215","doi-asserted-by":"crossref","first-page":"W297","DOI":"10.1093\/nar\/gkt380","article-title":"MoMA-LigPath: a web server to simulate protein-ligand unbinding","volume":"41","author":"Devaurs","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0220","doi-asserted-by":"crossref","first-page":"i116","DOI":"10.1093\/bioinformatics\/bti1017","article-title":"A path planning approach for computing large-amplitude motions of flexible molecules","volume":"21","author":"Cort\u00e9s","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0225","first-page":"1172","article-title":"Sitecomp: a server for ligand binding site analysis in protein structures","volume":"28","author":"Lin","year":"2012","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0230","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmgm.2015.10.005_bib0235","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/bioinformatics\/btg430","article-title":"The Jalview Java alignment editor","volume":"20","author":"Clamp","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1097-2765(05)00089-4","article-title":"Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine","volume":"6","author":"Walker","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jmgm.2015.10.005_bib0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326315300656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326315300656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:52:59Z","timestamp":1761079979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326315300656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":49,"alternative-id":["S1093326315300656"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2015.10.005","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A structural insight into the inhibitory mechanism of an orally active PI3K\/mTOR dual inhibitor, PKI-179 using computational approaches","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}